The heart failure revascularisation trial (HEART): Rationale, design and methodology

J. G F Cleland, N. Freemantle, S. G. Ball, R. S. Bonser, P. Camici, S. Chattopadhyay, D. Dutka, J. Eastaugh, J. Hampton, S. Large, M. S. Norell, D. J. Pennell, J. Pepper, S. Sanda, R. Senior, D. Smith

Research output: Contribution to journalArticle

Abstract

Background: Most patients with heart failure due to left ventricular systolic dysfunction (LVSD) secondary to coronary artery disease (CAD) have evidence of myocardium in jeopardy (reversible ischaemia and/or stunning hibernation). It is not known whether revascularisation in such cases is safe or beneficial. Aims: To determine whether revascularisation will improve the survival of patients with LVSD and heart failure secondary to CAD and myocardium in jeopardy. Methods: This is a randomised controlled trial comparing revascularisation or not, in addition to optimal medical therapy with ACE inhibitors, beta-blockers, aldosterone antagonists and an anti-thrombotic agent. Patients must have heart failure requiring treatment with diuretics, a left ventricular ejection fraction <35% and evidence of coronary disease. Myocardial viability and ischaemia are assessed by a broad range of techniques including stress echocardiography and nuclear imaging. All imaging tests are reviewed in core laboratories to ensure uniform reporting. Any conventional revascularisation technique is permitted. The primary outcome measure is all cause mortality. Symptoms, quality of life and health economic issues will also be explored. Assuming an annual mortality of 10% in the control group and allowing for substantial cross-over rates, a study of 800 patients followed for 5 years has 80% power with an alpha of 0.05 (two-sided) to show a 25% reduction in mortality with revascularisation. Results: At the time of writing 180 patients have been screened for inclusion, 111 have consented to participate and 70 have been randomised. The results of viability testing are awaited in 22 patients. Twenty-six patients had been investigated for myocardial viability and/or by angiography prior to consent, as part of the routine practice in that cardiology department. Of 68 patients who have completed assessment only after consent, 47 (69%) were included. The principal reason for drop-out between consent and randomisation was lack of evidence of myocardial ischaemia or hibernation. Conclusion: The HEART trial will help to determine whether investigation of myocardial ischaemia and/or viability with a view to revascularisation should become part of the routine care of patients with heart failure due to LVSD and CAD.

Original languageEnglish
Pages (from-to)295-303
Number of pages9
JournalEuropean Journal of Heart Failure
Volume5
Issue number3
DOIs
Publication statusPublished - 2003

Fingerprint

Heart Failure
Left Ventricular Dysfunction
Myocardial Ischemia
Coronary Artery Disease
Mortality
Myocardium
Myocardial Stunning
Systolic Heart Failure
Mineralocorticoid Receptor Antagonists
Stress Echocardiography
Hibernation
Random Allocation
Cardiology
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Stroke Volume
Coronary Disease
Patient Care
Angiography
Ischemia

Keywords

  • Heart failure
  • Heart study
  • Left ventricular systolic dysfunction
  • Revascularisation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cleland, J. G. F., Freemantle, N., Ball, S. G., Bonser, R. S., Camici, P., Chattopadhyay, S., ... Smith, D. (2003). The heart failure revascularisation trial (HEART): Rationale, design and methodology. European Journal of Heart Failure, 5(3), 295-303. https://doi.org/10.1016/S1388-9842(03)00056-4

The heart failure revascularisation trial (HEART) : Rationale, design and methodology. / Cleland, J. G F; Freemantle, N.; Ball, S. G.; Bonser, R. S.; Camici, P.; Chattopadhyay, S.; Dutka, D.; Eastaugh, J.; Hampton, J.; Large, S.; Norell, M. S.; Pennell, D. J.; Pepper, J.; Sanda, S.; Senior, R.; Smith, D.

In: European Journal of Heart Failure, Vol. 5, No. 3, 2003, p. 295-303.

Research output: Contribution to journalArticle

Cleland, JGF, Freemantle, N, Ball, SG, Bonser, RS, Camici, P, Chattopadhyay, S, Dutka, D, Eastaugh, J, Hampton, J, Large, S, Norell, MS, Pennell, DJ, Pepper, J, Sanda, S, Senior, R & Smith, D 2003, 'The heart failure revascularisation trial (HEART): Rationale, design and methodology', European Journal of Heart Failure, vol. 5, no. 3, pp. 295-303. https://doi.org/10.1016/S1388-9842(03)00056-4
Cleland, J. G F ; Freemantle, N. ; Ball, S. G. ; Bonser, R. S. ; Camici, P. ; Chattopadhyay, S. ; Dutka, D. ; Eastaugh, J. ; Hampton, J. ; Large, S. ; Norell, M. S. ; Pennell, D. J. ; Pepper, J. ; Sanda, S. ; Senior, R. ; Smith, D. / The heart failure revascularisation trial (HEART) : Rationale, design and methodology. In: European Journal of Heart Failure. 2003 ; Vol. 5, No. 3. pp. 295-303.
@article{1ff9e9d64b14478e89d1c60973999f1e,
title = "The heart failure revascularisation trial (HEART): Rationale, design and methodology",
abstract = "Background: Most patients with heart failure due to left ventricular systolic dysfunction (LVSD) secondary to coronary artery disease (CAD) have evidence of myocardium in jeopardy (reversible ischaemia and/or stunning hibernation). It is not known whether revascularisation in such cases is safe or beneficial. Aims: To determine whether revascularisation will improve the survival of patients with LVSD and heart failure secondary to CAD and myocardium in jeopardy. Methods: This is a randomised controlled trial comparing revascularisation or not, in addition to optimal medical therapy with ACE inhibitors, beta-blockers, aldosterone antagonists and an anti-thrombotic agent. Patients must have heart failure requiring treatment with diuretics, a left ventricular ejection fraction <35{\%} and evidence of coronary disease. Myocardial viability and ischaemia are assessed by a broad range of techniques including stress echocardiography and nuclear imaging. All imaging tests are reviewed in core laboratories to ensure uniform reporting. Any conventional revascularisation technique is permitted. The primary outcome measure is all cause mortality. Symptoms, quality of life and health economic issues will also be explored. Assuming an annual mortality of 10{\%} in the control group and allowing for substantial cross-over rates, a study of 800 patients followed for 5 years has 80{\%} power with an alpha of 0.05 (two-sided) to show a 25{\%} reduction in mortality with revascularisation. Results: At the time of writing 180 patients have been screened for inclusion, 111 have consented to participate and 70 have been randomised. The results of viability testing are awaited in 22 patients. Twenty-six patients had been investigated for myocardial viability and/or by angiography prior to consent, as part of the routine practice in that cardiology department. Of 68 patients who have completed assessment only after consent, 47 (69{\%}) were included. The principal reason for drop-out between consent and randomisation was lack of evidence of myocardial ischaemia or hibernation. Conclusion: The HEART trial will help to determine whether investigation of myocardial ischaemia and/or viability with a view to revascularisation should become part of the routine care of patients with heart failure due to LVSD and CAD.",
keywords = "Heart failure, Heart study, Left ventricular systolic dysfunction, Revascularisation",
author = "Cleland, {J. G F} and N. Freemantle and Ball, {S. G.} and Bonser, {R. S.} and P. Camici and S. Chattopadhyay and D. Dutka and J. Eastaugh and J. Hampton and S. Large and Norell, {M. S.} and Pennell, {D. J.} and J. Pepper and S. Sanda and R. Senior and D. Smith",
year = "2003",
doi = "10.1016/S1388-9842(03)00056-4",
language = "English",
volume = "5",
pages = "295--303",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "John Wiley & Sons, Ltd",
number = "3",

}

TY - JOUR

T1 - The heart failure revascularisation trial (HEART)

T2 - Rationale, design and methodology

AU - Cleland, J. G F

AU - Freemantle, N.

AU - Ball, S. G.

AU - Bonser, R. S.

AU - Camici, P.

AU - Chattopadhyay, S.

AU - Dutka, D.

AU - Eastaugh, J.

AU - Hampton, J.

AU - Large, S.

AU - Norell, M. S.

AU - Pennell, D. J.

AU - Pepper, J.

AU - Sanda, S.

AU - Senior, R.

AU - Smith, D.

PY - 2003

Y1 - 2003

N2 - Background: Most patients with heart failure due to left ventricular systolic dysfunction (LVSD) secondary to coronary artery disease (CAD) have evidence of myocardium in jeopardy (reversible ischaemia and/or stunning hibernation). It is not known whether revascularisation in such cases is safe or beneficial. Aims: To determine whether revascularisation will improve the survival of patients with LVSD and heart failure secondary to CAD and myocardium in jeopardy. Methods: This is a randomised controlled trial comparing revascularisation or not, in addition to optimal medical therapy with ACE inhibitors, beta-blockers, aldosterone antagonists and an anti-thrombotic agent. Patients must have heart failure requiring treatment with diuretics, a left ventricular ejection fraction <35% and evidence of coronary disease. Myocardial viability and ischaemia are assessed by a broad range of techniques including stress echocardiography and nuclear imaging. All imaging tests are reviewed in core laboratories to ensure uniform reporting. Any conventional revascularisation technique is permitted. The primary outcome measure is all cause mortality. Symptoms, quality of life and health economic issues will also be explored. Assuming an annual mortality of 10% in the control group and allowing for substantial cross-over rates, a study of 800 patients followed for 5 years has 80% power with an alpha of 0.05 (two-sided) to show a 25% reduction in mortality with revascularisation. Results: At the time of writing 180 patients have been screened for inclusion, 111 have consented to participate and 70 have been randomised. The results of viability testing are awaited in 22 patients. Twenty-six patients had been investigated for myocardial viability and/or by angiography prior to consent, as part of the routine practice in that cardiology department. Of 68 patients who have completed assessment only after consent, 47 (69%) were included. The principal reason for drop-out between consent and randomisation was lack of evidence of myocardial ischaemia or hibernation. Conclusion: The HEART trial will help to determine whether investigation of myocardial ischaemia and/or viability with a view to revascularisation should become part of the routine care of patients with heart failure due to LVSD and CAD.

AB - Background: Most patients with heart failure due to left ventricular systolic dysfunction (LVSD) secondary to coronary artery disease (CAD) have evidence of myocardium in jeopardy (reversible ischaemia and/or stunning hibernation). It is not known whether revascularisation in such cases is safe or beneficial. Aims: To determine whether revascularisation will improve the survival of patients with LVSD and heart failure secondary to CAD and myocardium in jeopardy. Methods: This is a randomised controlled trial comparing revascularisation or not, in addition to optimal medical therapy with ACE inhibitors, beta-blockers, aldosterone antagonists and an anti-thrombotic agent. Patients must have heart failure requiring treatment with diuretics, a left ventricular ejection fraction <35% and evidence of coronary disease. Myocardial viability and ischaemia are assessed by a broad range of techniques including stress echocardiography and nuclear imaging. All imaging tests are reviewed in core laboratories to ensure uniform reporting. Any conventional revascularisation technique is permitted. The primary outcome measure is all cause mortality. Symptoms, quality of life and health economic issues will also be explored. Assuming an annual mortality of 10% in the control group and allowing for substantial cross-over rates, a study of 800 patients followed for 5 years has 80% power with an alpha of 0.05 (two-sided) to show a 25% reduction in mortality with revascularisation. Results: At the time of writing 180 patients have been screened for inclusion, 111 have consented to participate and 70 have been randomised. The results of viability testing are awaited in 22 patients. Twenty-six patients had been investigated for myocardial viability and/or by angiography prior to consent, as part of the routine practice in that cardiology department. Of 68 patients who have completed assessment only after consent, 47 (69%) were included. The principal reason for drop-out between consent and randomisation was lack of evidence of myocardial ischaemia or hibernation. Conclusion: The HEART trial will help to determine whether investigation of myocardial ischaemia and/or viability with a view to revascularisation should become part of the routine care of patients with heart failure due to LVSD and CAD.

KW - Heart failure

KW - Heart study

KW - Left ventricular systolic dysfunction

KW - Revascularisation

UR - http://www.scopus.com/inward/record.url?scp=0012650167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0012650167&partnerID=8YFLogxK

U2 - 10.1016/S1388-9842(03)00056-4

DO - 10.1016/S1388-9842(03)00056-4

M3 - Article

C2 - 12798827

AN - SCOPUS:0012650167

VL - 5

SP - 295

EP - 303

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 3

ER -